XENON PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.6 USD | +0.60% |
|
-0.96% | -16.19% |
Presenter SpeechSimon Pimstone (Executives)Welcome to Xenon's 2023 AGM. My name is Simon Pimst...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
2024-06-04
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
38.37
USD
Average target price
58.22
USD
Spread / Average Target
+51.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.19% | 2.9B | |
| +9.74% | 118B | |
| +10.77% | 106B | |
| -10.94% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.30% | 15.97B | |
| +6.56% | 14.03B | |
| +17.26% | 11.67B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Transcript : Xenon Pharmaceuticals Inc. - Shareholder/Analyst Call
